Patients say they'll adhere. Clinicians say they'll adopt the new protocol. Support programs report high enrollment. But outcomes don't move. lumenx runs hundreds of behaviorally-informed conversations to surface what actually drives behavior, not what people report.
Request a demoSurveys measure the first. lumenx measures the second. Adherence surveys report 80% compliance. Real-world data shows 50%. The gap isn't dishonesty. It's the difference between what people intend and what their behavior actually looks like. Traditional research methods can't reach it.
Readmission rates stay stubbornly high despite patient education programs. The behavioral drivers of readmission live in routines, environment, and social context.
Surface the behavioral drivers of readmission that patient education alone can't address.
Regulatory agencies increasingly expect patient voice in drug development, but traditional methods capture stated preferences, not lived experience.
Build disease conceptual models, surface unmet needs, and generate PFDD-ready evidence at scale.
Positioning decisions are made on stated preferences and advisory boards. How patients and prescribers actually think about a condition is different.
Understand how patients and prescribers think about a condition before you commit to a positioning.
Participants disengage for behavioral reasons protocol designers can't see. And endpoints may not measure what predicts real-world behavior.
Uncover why participants disengage and whether you're measuring what predicts real-world behavior.
Prescribing decisions are shaped by habit, peer influence, and context, not just clinical data. Stated preferences don't explain real-world practice.
Understand what actually shifts treatment decisions in practice.
Start a conversation about what behavioral evidence could look like for your team.